Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.

ABSTRACT: Safinamide is a highly selective, reversible MAO B-inhibitor recently marketed in European and North American countries. To better define clinical indications regarding motor and non-motor symptoms, targeted population and safety of this compound, ten movement disorders specialists, experts in their field, convened and developed a panel of statements on: the role of glutamate in Parkinson's disease, introduction to fluctuations, efficacy of safinamide on motor symptoms, motor complications and non-motor symptoms, quality of life, safety of safinamide and target population for use. Strong consensus was reached for all the statements on the efficacy of safinamide on motor symptoms, motor fluctuations, quality of life and safety. Among non-motor symptoms, a positive consensus was reached for

SUBMITTER: Stocchi F 

PROVIDER: S-EPMC8861053 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature